Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02730403 · ClinicalTrials.gov registry record
TAU Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With CTN-0051
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 211
- Enrollment target
NCT02730403: Completed study, sponsored by NYU Langone Health.
NCT02730403 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 211 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02730403 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 211 participants
- Enrollment target
Study Summary
This is an observational, "ancillary study" intended to describe opioid use among opioid use disorder patients following their discharge into the community from inpatient detoxification and/or short-term residential treatment programs affiliated with parent study CTN-0051, which assessed the comparative effectiveness of extended release injectable naltrexone (XR-NTX, Vivitrol®), an opioid antagonist recently approved and indicated for the prevention of relapse to opioid dependence, versus buprenorphine-naloxone (BUP-NX, Suboxone®), a high affinity partial agonist indicated for maintenance treatment of opioid dependence, as pharmacotherapeutic aids to recovery.
Primary Outcome
Days of use during the first 4 weeks post discharge
Interventions
- OTHER Treatment As Usual
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2016-06-01 |
| Est. Completion | 2017-01-30 |
What the finished NCT02730403 record still lists
NCT02730403 is an observational study that tracks outcomes without assigning an intervention. The registered 211 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Treatment As Usual is the first listed.
NCT02730403 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02730403 about?
NCT02730403 is a clinical study titled "TAU Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With CTN-0051". This is an observational, "ancillary study" intended to describe opioid use among opioid use disorder patients following their discharge into the community from inpatient detoxification and/or short-term residential treatment programs affiliated with parent study CTN-0051, which assessed the compara...
What is the current status of trial NCT02730403?
This trial is currently completed. The enrollment target is 211 participants. The study started on 2016-06-01. Estimated completion is 2017-01-30.
What interventions are being tested in trial NCT02730403?
The interventions under investigation include: Treatment As Usual (OTHER).
Who is sponsoring clinical trial NCT02730403?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06698796 · 211 participants · Phase 3
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI